Epithelial ovarian cancer

Current Problems in Surgery

Volumn 36, Issue 1, 1999, Pages 11-53

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CARCINOMA; CHILD; FEMALE; HUMAN; MIDDLE AGED; NEWBORN; OVARY TUMOR; REVIEW; UNITED STATES;

ADULT; AGED; CARCINOMA; CHILD; FEMALE; HUMANS; INFANT, NEWBORN; MIDDLE AGED; OVARIAN NEOPLASMS; UNITED STATES;

EID: 0032617244     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (97)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Hoskins WJ. The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:59-71.
3. Ozols RF, Rubin SC, Thomas G, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Ferez CA, Young RC, editors. Principles and practice of gynecologic oncology. 2nd edition. Philadelphia: Lippincott-Raven Publishers; 1997. p. 919-86.
4. Brinton LA, Hoover RN. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. 2nd edition. Philadelphia: Lippincott-Raven Publishers; 1997. p. 3-29.
5. Averette HE, Nguyen HN. The role of prophylactic oophorectomy in cancer prevention. Gynecol Oncol 1994;55:S38-41.
6. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attribute risk of breast and ovarian cancer. Cancer 1996;77:2318-24.
7. Lynch HT, Watson P, Bewtra C, et al. Hereditary ovarian cancer: Heterogeneity in age at diagnosis. Cancer 1991;67:1460-6.
8. Lynch HT, Smyrk T, Lynch JF. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 1996:69:38-43.
9. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA 1. Science 1994;266:66-71.
10. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55:S4-14.
11. Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994;96:516-20.
12. Piver MS, Jishi MF, Tsukada Y, Nava G. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1993 ;71:2751-5.
13. Tobacman JK, Green MH, Tucker MA, Costa J, Kase R, Fraumeni JF Jr. Intraabdominal carcinomatosis after prophylactic oophorectomy in ovariancancer-prone families. Lancet 1982;2:795-7.
14. Hartge P, Whittemore AS, Itnyre J, McGowan L, Cramer D. The Collaborative Ovarian Cancer Group: Rates and risks of ovarian cancer subgroups of white women in the United States. Obstet Gynecol 1994;84:760-4.
15. Hammond CB. Menopause and hormone replacement therapy: An overview. Obstet Gynecol 1996;87:2S-15S.
16. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990; 163:1438-44.
17. Killackey MA, Neuwirth RS. Evaluation and management of the pelvic mass: A review of 540 cases. Obstet Gynecol 1988;71:319-22.
18. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
19. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988;71:751-6.
20. Malkasian GD, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988;159:341-6.
21. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988;72:659-64.
22. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993;306:1030-4.
23. Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation. Gynecol Oncol 1989:35:139-44.
24. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasono-graphie characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994; 170:81-5.
25. Fleischer AC, Cullinan JA, Kepple DM, Williams LL. Conventional and color Doppier transvaginal sonography of pelvic masses: a comparison of relative histologie specificities. J Ultrasound Med 1993;12:705-12.
26. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdorninal ultrasound screening for early ovarian cancer. BMJ 1989;299:1363-7.
27. van Nagell JR Jr, DePriest PD, Puis LE, et al. Ovarian cancer screening in asymptomatic postmenopausal women by transvaginal sonography. Cancer 1991;68:45862.
28. Karlan BY, Platt LD. Ovarian cancer screening: The role of ultrasound in early detection. Cancer 1995:76:2011-5.
29. Maly Z, Riss P, Deutinger J. Localization of blood vessels and qualitative assessment of blood flow in ovarian tumors. Obstet Gynecol 1995;85:33-6.
30. Kawai M, Kano T, Kikkawa F, Maeda O, Oguchi H, Tomoda Y. Transvaginal Doppler ultrasound with color flow imaging in the diagnosis of ovarian cancer. Obstet Gynecol 1992;79:163-7.
31. Schneider VL, Schneider A, Reed KL, Hatch K. Comparison of Doppler with twodimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol 1993;81:983-8.
32. Brooks SE. Preoperative evaluation of patients with suspected ovarian cancer. Gynecol Oncol 1994;55:S80-90.
33. Forstner R. Hricak H, Occhipinti KA, Powell CB, Frankel SD, Stern JL. Ovarian cancer: staging with CT and MR imaging. Radiology 1995;197:619-26.
34. Velebil P, Wingo PA, Xia Z, Wilcox LS, Peterson HB. Rate of hospitalization for gynecologic disorders among reproductive-age women in the United States. Obstet Gynecol 1995:86:764-9.
35. Westhoff C. Clark CJ. Benign ovarian cysts in England and Wales and in the United States. Br J Obstet Gynecol 1992;99:329-32.
36. Millar DM, Blake JM, Stringer DA. Hara H, Babiak C. Prepubertal ovarian cyst formation: 5 years' experience. Obstet Gynecol 1993;81:434-8.
37. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995;75:270-94.
38. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993;71:1581-90.
39. Peccatori F, Bonazzi C, Chiari S, Landoni F, Colombo N, Mangioni C. Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. Obstet Gynecol 1995;86:367-72.
40. Grimes D, Hughes JM. Use of multiphasic oral contraceptives and hospitalization of women with functional ovarian cysts in the United States. Obstet Gynecol 1989;73:1037-9.
41. Flynn M, Niloff JM. Minilaparotomy for the ambulatory management of ovarian cysts. Am J Obstet Gynecol 1995;173:1727-30.
42. Pittaway DE, Takacs P, Bauguess P. Laparoscopic adnexectomy: a comparison with laparotomy. Am J Obstet Gynecol 1994; 171:385-91.
43. Canis M, Mage G, Pouly JL, Wattiez A, Manhes H, Bruhat MA. Laparoscopic diagnosis of adnexal cystic masses: a 12-year experience with long-term follow-up. Obstet Gynecol 1994;83:707-12.
44. Nezhat F, Nezhat C, Welander CE, Benigno B. Four ovarian cancers diagnosed dur-ing laparoscopic management of 1011 women with adnexal masses. Am J Obstet Gynecol 1992; 167:790-6.
45. Mecke H, Lehmann-Willenbrock E, Ibrahim M, Semm K. Pelviscopic treatment of ovarian cysts in premenopausal women. Gynecol Obstet Invest 1992;34:36-42.
46. Robinson WR, Curtin JP, Morrow CP. Operative staging and conservative surgery in the management of low malignant potential ovarian tumors. Int J Gynecol Cancer 1992;2:113-8.
47. Menzin AW, Rubin SC, Noumoff JS, LiVolsi VA. The accuracy of a frozen section diagnosis of borderline ovarian malignancy. Gynecol Oncol 1995:59:183-5.
48. Curtin JP. Management of the adnexal mass. Gynecol Oncol 1994;55:S42-6.
49. Abu-Rustum NR, Barakat RR, Curtin JP. Ovarian and uterine disease in women with colorectal cancer. Obstet Gynecol 1997;89:85-7.
50. Koonings PP. Campbell K, Mishell DR, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10-year review. Obstet Gynecol 1989:74:921-6.
51. Hoskins WJ, McGuire WP, Homesley HD, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994:170:97480.
52. Parker WH, Levine RL, Howard FM, Sansone B, Berek JS. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994:179:733-7.
53. Childers JM, Lang J. Surwit EA, Hatch KD. Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol 1995:59:25-35.
54. Goldstein SR, Subramanyam B, Snyder JR, Beller U. Raghavendra BN, Beckman EM. The postmenopausal cystic adnexal mass: the potential role of ultrasound in conservative management. Obstet Gynecol 1989:73:8-10.
55. Andolf E, Jörgensen C. Cystic lesions in elderly women, diagnosed by ultrasound. Br J Obstet Gynaecol 1989:96:1076-9.
56. Wolf SI, Gosnik BB, Feldsman MR. Prevalence of simple adnexal cysts in postmenopausal women. Radiology 1991:180:65-71.
57. Kroon E, Andolf E. Diagnosis and follow-up of simple ovarian cysts detected by ultrasound in postmenopausal women. Obstet Gynecol 1995:85:211-4.
58. Stier EA, Barakat RA, Curtin JP, Brown CL, Jones WB, Hoskins WJ. Laparotomy to complete staging of presumed early ovarian cancer. Obstet Gynecol 1996:87:73740.
59. Hoskins WJ. Epithelial ovarian cancer: principles of primary surgery. Gynecol Oncol 1994;55:S91-6.
60. Hoskins WJ. Bundy BN, Thigpen JT. Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992:47:15966.
61. Girling JC, Soutier WP. Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: a topic for debate. Int J Gynecol Cancer 1996:6:81-4.
62. Curtin JP, Malik R, Venkatraman ES, Barakat RR. Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9-12.
63. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997:64:4-8.
64. Munkarah AR, Hallum AV, Morris M, et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:137.
65. Van Der Burg MEL, Van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithielial ovarian cancer. N Engl J Med 1995;332:629-34.
66. Hoskins WJ, Rubin SC, Dulaney E, et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian cancer. Gynecol Oncol 1989;34;365-71.
67. Copeland LJ, Gershenson DM, Wharton JT, et al. Microscopic disease at secondlook laparotomy in advanced ovarian cancer. Cancer 1985;55:472-8.
68. Gershenson DM, Copeland LJ, Wharton JT, et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985;55:1129-35.
69. Ozols RE Rubin SC, Dembo AJ, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology, 1st edition. Philadelphia: JB Lippincott Company; 1992. p. 731-81.
70. Rosenoff SH, Young RC, Anderson T, et al. Peritoneoscopy: a valuable staging tool in ovarian carcinoma. Ann Intern Med 1975:83:37-41.
71. Bagley CM, Young RC, Schein PS, et al. Ovarian cancer metastatic to the diaphragm frequently undiagnosed at laparotomy. Am J Obstet Gynecol 1973;116:397-400.
72. Quinn MA, Bishop GJ, Campbell JJ, et al. Laparoscopic follow-up of patients with ovarian cancer. Br J Obstet Gynaecol 1980;87:1132-9.
73. Xygakis AM, Politis GS, Michalas SP, et al. Second-look laparoscopy in ovarian cancer. J Reprod Med 1984;29:583-5.
74. Ozols RE, Fisher RI, Anderson T, et al. Peritoneoscopy in the management of ovarian cancer. Am J Obstet Gynecol 1981;140:611-9.
75. Berek JS, Griffiths CT, Leventhal JM. Laparoscopy for second-look evaluation in ovarian cancer. Obstet Gynecol 1981;58:192-8.
76. Rutledge EN. The second-look operation for ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:175-82.
77. Piver MS, Shashikant BL, Barlow JJ, et al. Second-look laparoscopy prior to proposed second-look laparotomy. Obstet Gynecol 1980;55:571-3.
78. Abu-Rustum NR, Barakat RR, Siegel PL, Venkatraman E, Curtin JP, Hoskins WJ. Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy? Obstet Gynecol 1996;88:549-53.
79. Casey AC, Farias-Eisner R, Pisani AL, et al. What is the role of reassessment laparoscopy in the management of gynecologic cancer in 1995? Gynecol Oncol 1996;60:454-61.
80. Janisch H, Schieder K, Koelbl H. Diagnostic versus therapeutic second-look surgery in patients with ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:191-200.
81. Rubin SC, Lewis JL. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988;8:75-91.
82. Montz FJ. Complications of laparoscopic surgery in gynecology. J Gynecologic Techniques 1995;1: 125-34.
83. Barakat RR, Fennelly D, Pizzuto F, Curtin JP, Brown C, Venkatraman ES, Hoskins WJ. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease [abstract]. Eur J Gynecol Oncol 1997;18:161-3.
84. Rubin SC, Dulaney ED, Markman M, et al. Peritoneal cytology as an indicator of disease in patients with residual ovarian cancer. Obstet Gynecol 1988;71:851-3.
85. Herd J, Fowler JM, Shenson D, Lacy S, Montz FJ. Laparoscopic para-aortic lymph node sampling: development of a technique. Gynecol Oncol 1992;44:271-6.
86. Eisenkop SM, Friedman RL, Wang H. Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer 1995;76:1606-14.
87. Rubin SC, Hoskins WJ, Benjamin I, Lewis JL Jr. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 1989;34:16-9.
88. Rubin SC, Benjamin I, Hoskins WJ, Pierce VK, Lewis JL Jr. Intestinal surgery in gynecologic oncology. Gynecol Oncol 1989;34:30-3.
89. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med 1990;322:1021-7.
90. Ahmed FY, Wiltshaw E, A'Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968-75.
91. Thomas GM. Radiotherapy in early ovarian cancer. Gynecol Oncol 1994;55:S73-9.
92. Vergote IB, Vergoe-De Vos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69:741-9.
93. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
94. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus Cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992; 10:706-17.
95. Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992;10:718-26.
96. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-5.
97. Levin L, Hryniuk Wm. Dose intensity analysis of chemotherapy regimens in ovarian cancer. J Clin Oncol 1987;5:756-67.